1-6 of 6
Imelda Parker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy
Journal: Blood
Blood (2021) 138 (Supplement 1): 2756.
https://doi.org/10.1182/blood-2021-145530
Published: 2021
Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3242.
https://doi.org/10.1182/blood-2018-99-112375
Published: 2018
Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3163.
https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163
Published: 2017
Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD
Journal: Blood
Blood (2016) 128 (22): 3237.
https://doi.org/10.1182/blood.V128.22.3237.3237
Published: 2016
Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Peter O'Gorman, MD PhD, Michael E O'Dwyer, MD, Oonagh Gilligan, MD, John Quinn, MD PhD, Mark Coyne, MD, Janusz Krawczyk, MD, Philip T Murphy, MD, Lourdes del Rosario McAlester, Orna Harraghy, Orlaith Cormican, Elizabeth Lenihan, Keith Egan, Meegahage Ratnakanthi Perera, MD, Gerard Crotty, Patrick J Hayden, MD, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Kathleen Scott, PhD, Imelda Parker, PhD, Michele Cunnane, Jacinta Marron, Aoife Connell, Elizabeth Coghlan, Jacob P. Laubach, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 2117.
https://doi.org/10.1182/blood.V128.22.2117.2117
Published: 2016
Journal Articles

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Amjad Hayat, MBBS, PhD, David O'Brien, Fiona Quinn, PhD, Fionnuala Keane, PhD, Imelda Parker, PhD, Johanna Kelly, BSc, Marzena Wieczorkowska, Gerard Crotty, MD, Maeve Leahy, MD, Helen Enright, MD, Brian Hennessy, MD, Mary Cahill, MB, Elisabeth A. Vandenberghe, MB, PhD
Journal: Blood
Blood (2012) 120 (21): 1791.
https://doi.org/10.1182/blood.V120.21.1791.1791
Published: 2012